BGI Genomics to Inject 149 Million Yuan in Equity Investment Fund

MT Newswires Live09-11

BGI Genomics (SHE:300676) invested 149 million yuan in an equity investment fund, according to a Tuesday disclosure on the Shenzhen Stock Exchange.

The fund, Shaoxing Meiyue Medical Industry Equity Investment Partnership (Limited Partnership), will raise a capital of 500 million yuan.

The Chinese genomics services provider will own 29.8% of the fund's capital.

The other partners, Keqiao Jinkai New Materials, will own 70% of the fund after injecting 350 million yuan, while Kemei Health Management (Shaoxing Keqiao) will own the remaining 0.2% after injecting 1 million yuan.

Price (RMB): ¥34.76, Change: ¥-0.030, Percent Change: -0.09%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment